reamberin and Autoimmune-Diseases

The aim of the study was to develop a new strategy of dosing a Reamberine 1,5% infusion solution on an individual basis for patients with LADA 1.5 diabetes mellitus (DM) and new methods for estimating the regulation and functioning of metabolic pathways associated with the production and transformation of succinic acid. The use of Reamberin led to the reduction of average, maximum and minimum blood glucose and HBA1c levels. The study revealed a decrease of proteinuria, serum creatinine level, and albumin/creatinine ratio in urine Patients given intensive therapy with insulin and Reamberin underwent significant reduction of blood Na', K+ and chlorine levels and increased Na+/K+, Mg++ and Ca++ ratios. Morning and evening concentrations of ACTH decreased while cortisol levels increased at 8.00 and 18.00. IRI level decreased, T3 and T4 levels increased both at 8.00 and 18.00 when TSH concentration was reduced The percentage of patients unsatisfied with QL (based on the Diabetes QL scale) among those taking Reamberine diminished while that of the patients satisfied with QL increased. The first data on dynamics of plasma protein expression during Reamberin therapy are presented

Topics: Adult; Autoimmune Diseases; Diabetes Mellitus; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Insulin; Male; Meglumine; Middle Aged; Precision Medicine; Succinates; Treatment Outcome; Young Adult